131 related articles for article (PubMed ID: 35106515)
21. RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers.
Xia L; Tian E; Yu M; Liu C; Shen L; Huang Y; Wu Z; Tian J; Yu K; Wang Y; Xie Q; Zhu D
J Exp Clin Cancer Res; 2022 Apr; 41(1):155. PubMed ID: 35459193
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy enhances CXCR3
Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
[TBL] [Abstract][Full Text] [Related]
23. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
24. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation.
Wong YC; Holzbaur EL
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4439-48. PubMed ID: 25294927
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
26. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Ebert PJR; Cheung J; Yang Y; McNamara E; Hong R; Moskalenko M; Gould SE; Maecker H; Irving BA; Kim JM; Belvin M; Mellman I
Immunity; 2016 Mar; 44(3):609-621. PubMed ID: 26944201
[TBL] [Abstract][Full Text] [Related]
27. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).
Yan Y; Zheng L; Du Q; Yazdani H; Dong K; Guo Y; Geller DA
Cancer Lett; 2021 May; 506():95-106. PubMed ID: 33689775
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus (FK506) suppresses TNF-α-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts.
Aomatsu T; Imaeda H; Takahashi K; Fujimoto T; Kasumi E; Yoden A; Tamai H; Fujiyama Y; Andoh A
Int J Mol Med; 2012 Nov; 30(5):1152-8. PubMed ID: 22895606
[TBL] [Abstract][Full Text] [Related]
29. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
30. Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes.
Qi XF; Kim DH; Yoon YS; Jin D; Huang XZ; Li JH; Deung YK; Lee KJ
J Cell Physiol; 2009 Sep; 220(3):690-7. PubMed ID: 19472212
[TBL] [Abstract][Full Text] [Related]
31. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
32. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
Bronger H; Singer J; Windmüller C; Reuning U; Zech D; Delbridge C; Dorn J; Kiechle M; Schmalfeldt B; Schmitt M; Avril S
Br J Cancer; 2016 Aug; 115(5):553-63. PubMed ID: 27490802
[TBL] [Abstract][Full Text] [Related]
33. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells.
Borgogni E; Sarchielli E; Sottili M; Santarlasci V; Cosmi L; Gelmini S; Lombardi A; Cantini G; Perigli G; Luconi M; Vannelli GB; Annunziato F; Adorini L; Serio M; Crescioli C
Endocrinology; 2008 Jul; 149(7):3626-34. PubMed ID: 18372324
[TBL] [Abstract][Full Text] [Related]
34. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
35. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
36. PDGF synergistically enhances IFN-gamma-induced expression of CXCL10 in blood-derived macrophages: implications for HIV dementia.
Dhillon NK; Peng F; Ransohoff RM; Buch S
J Immunol; 2007 Sep; 179(5):2722-30. PubMed ID: 17709485
[TBL] [Abstract][Full Text] [Related]
37. The Expression of CXCL10/CXCR3 and Effect of the Axis on the Function of T Lymphocyte Involved in Oral Lichen Planus.
Fang J; Wang C; Shen C; Shan J; Wang X; Liu L; Fan Y
Inflammation; 2019 Jun; 42(3):799-810. PubMed ID: 30467622
[TBL] [Abstract][Full Text] [Related]
38. Insulin regulation of mitogen-activated protein kinase kinase (MEK), mitogen-activated protein kinase and casein kinase in the cell nucleus: a possible role in the regulation of gene expression.
Kim SJ; Kahn CR
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):621-7. PubMed ID: 9169593
[TBL] [Abstract][Full Text] [Related]
39. IL-29 Enhances CXCL10 Production in TNF-α-stimulated Human Oral Epithelial Cells.
Hosokawa Y; Hosokawa I; Shindo S; Ozaki K; Matsuo T
Immunol Invest; 2017 Aug; 46(6):615-624. PubMed ID: 28753407
[TBL] [Abstract][Full Text] [Related]
40. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
